玻璃体腔注射康柏西普治疗早产儿视网膜病变的疗效观察  

Efficacy of Intravitreal Injection of Conbercept for the Treatment of Retinopathy of Prematurity

作　　者：赵磊[1] 孔令军[1,2] ZHAO Lei;KONG Ling-jun(Children's Hospital of Soochow University,Suzhou,Jiangsu,215003,China;Children's Hospital of WujiangDistrict,Suzhou,Jiangsu,215200,China)

机构地区：[1]苏州大学附属儿童医院,江苏苏州215003 [2]苏州市吴江区儿童医院,江苏苏州215200

出　　处：《中国血液流变学杂志》2021年第3期380-384,共5页Chinese Journal of Hemorheology

基　　金：苏州市2020年度第二十九批科技发展计划(民生科技)项目(SYS2020153),中华国际医学交流基金会中青年医学研究专项基金2020年度抗感染领域科研资助项目(Z-2018-35-2003),2020年度吴江区第二批“科教兴卫”项目(WWK202025)。

摘　　要：目的观察玻璃体腔注射康柏西普治疗早产儿视网膜病变(ROP)的疗效。方法回顾性病例研究。选择2019年5月—2020年9月行ROP筛查并诊断为急进型后极部ROP(AP-ROP)、阈值期ROP或阈值前期1型ROP的患儿21例(42眼)纳入研究。所有患儿在确诊后48 h内接受首次玻璃体腔注射康柏西普0.025 mL(含康柏西普0.25 mg)治疗。术后前3 d检查患儿眼前节情况,术后1周散瞳复查眼底,根据复查情况调整随访时间。随访时间至少6个月。对术后无反应或复发的患儿,重复注射治疗。结果42只眼中,41只眼经一次玻璃体腔注射康柏西普治疗好转,占97.6%。治疗后无反应1只眼,占2.4%,外院再次抗血管内皮生长因子治疗后好转。随访中有5只眼复发,占11.9%,其中AP-ROP 3只眼,3期病变伴附加病变2只眼,给予二次注射治疗后好转。随访6个月,40只眼视网膜血管发育至周边近锯齿缘,治愈,占95.2%。所有患眼均未见与药物或治疗方式相关的眼部及全身并发症。结论玻璃体腔注射康柏西普治疗ROP有效,严重病例复发风险较高。Objective To observe the efficacy of intravitreal injection of Conbercept for the treatment of retinopathy of prematurity(ROP).Methods A retrospective study.21 children(42 eyes)with acute aggressive posterior ROP(AP-ROP),threshold ROP or pre-threshold type 1 ROP diagnosed by ROP screening in Children's Hospital of Soochow University from May 2019 to September 2020 were enrolled in this study.All children were treated with the first intravitreal injection of Conbercept 0.025 mL(0.25 mg)within 48 hours after diagnosis.Ocular anterior segment were examined in the first 3 days after surgery.Fundus examination was performed 7 days after injection.Follow-up time was adjusted according to the review.Follow-up time was at least 6 months.Intravitreal injection of Conbercept treatment was repeated for children with no response or recurrence after surgery.Results In 42 eyes,41 eyes(97.6%)improved after one intravitreal injection of Conbercept treatment.1 eye(2.4%)had no response after treatment.The patient improved after anti-VEGF treatment in another hospital.During the follow-up,5 eyes(11.9%)relapsed,including AP-ROP 3 eyes,ROP Tage 3 with plus lesion 2 eyes,which improved after the second injection treatment.After 6 months of follow-up,40 eyes(95.2%)had retinal vessels that continued to grow close to ora serrata and were cured.None of the patients had ocular or systemic complications related to medication or treatment.Conclusion Intravitreal injection of Compercept is effective in the treatment of ROP,with a higher risk of recurrence in severe cases.

关 键 词：早产儿视网膜病变 康柏西普 玻璃体腔注射 

分 类 号：R722.6[医药卫生—儿科]